FDA approves cancer drug Stivarga for advanced gastrointestinal stromal tumors
The US Food and Drug Administration today announced it has expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be removed and do not respond to other forms of approved… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
February 25, 2013 -- The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors (for specialized target groups only)
Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments (Source: Bayer Company News)
Source: Bayer Company News - February 25, 2013 Category: Pharmaceuticals Source Type: news

FDA approves Stivarga for advanced gastrointestinal stromal tumors
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and that no longer respond to other FDA-approved treatments for this disease. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 25, 2013 Category: American Health Source Type: news

Resecting Residual Gastrointestinal Stromal Tumors Improved Survival
SAN FRANCISCO (IMNG) - Surgically removing residual gastrointestinal stromal tumors in patients who respond to imatinib therapy significantly increased time to tumor progression to 88 months, compared... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - January 25, 2013 Category: Cancer & Oncology Source Type: news

Seeking patients with renal cell carcinoma for interviews
Dear Cancer Patient:We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who arecurrently taking orconsidering taking a chemotherapy agent.These interviews are scheduled forMonday, September 29 and the morning ofTuesday, September 30  in our offices at:Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview will last 60 minutes and the cash honorarium is $150This is not sales. All information will be completely confidential. Please call me at312-604-40...
Source: Kidney Cancer Association - September 11, 2008 Category: Urology & Nephrology Source Type: news

Seeking patients with renal cell carcinoma for interviews
Dear Cancer Patient: We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who are currently taking or considering taking  a chemotherapy agent. These interviews are scheduled for Monday, September 29 and the morning of Tuesday, September 30   in our offices at: Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview  will last 60 minutes and the cash honorarium is $150 This is not sales. All information will be completely confidential.  Please ca...
Source: Kidney Cancer Association - September 11, 2008 Category: Urology & Nephrology Source Type: news

Seeking patients with renal cell carcinoma for interviews
Dear Cancer Patient:We are conducting one-on-one interviews with patients who have renal cell carcinoma or gastrointestinal stromal tumors (GIST) and who arecurrently taking orconsidering taking a chemotherapy agent.These interviews are scheduled forMonday, September 29 and the morning ofTuesday, September 30  in our offices at:Murray Hill Center 444 No. Michigan Avenue Room 700 (Across the street from Tribune Tower) Chicago, IL. The interview will last 60 minutes and the cash honorarium is $150This is not sales. All information will be completely confidential. Please call me at312-604-40...
Source: Kidney Cancer Association - September 11, 2008 Category: Urology & Nephrology Source Type: news

NCCN Announces Release of Gastrointestinal Stromal Tumors (GIST) Task Force Report
Hollywood, FL, March 11, 2004 – The National Comprehensive Cancer Network (NCCN) today introduces The NCCN Gastrointestinal Stromal Tumors (GIST) Task Force Report. The report, an expansion on The NCCN Sarcoma Clinical Practice Guidelines in Oncology, outlines the current thinking about the optimal management of patients with GIST. Though an uncommon cancer, GIST is increasingly recognized after experts reported that imatinib (Gleevec, Novartis Pharmaceuticals) an oral cancer therapy which tar... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 11, 2004 Category: Cancer & Oncology Source Type: news